SciVision Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

SciVision Biotech şirketinin toplam hissedar öz sermayesi NT$1.7B ve toplam borcu NT$206.1M olup, bu da borç-öz sermaye oranını 12.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$2.3B ve NT$632.9M dir. SciVision Biotech 'in FAVÖK'ü NT$232.4M faiz karşılama oranı -19.8 dur. Şirketin NT$861.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

12.1%

Borç/özkaynak oranı

NT$206.13m

Borç

Faiz karşılama oranı-19.8x
NakitNT$861.28m
EşitlikNT$1.70b
Toplam yükümlülüklerNT$632.94m
Toplam varlıklarNT$2.33b

Son finansal sağlık güncellemeleri

Recent updates

Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

Oct 11
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Aug 30
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

Jul 22
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28
SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Jun 14
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Jun 04
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01
Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25
Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05
Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01
Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25
Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1786 'nin kısa vadeli varlıkları ( NT$1.2B ) kısa vadeli yükümlülüklerini ( NT$362.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1786 şirketinin kısa vadeli varlıkları ( NT$1.2B ) uzun vadeli yükümlülüklerini ( NT$270.6M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1786 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1786 'nin borç/öz sermaye oranı son 5 yılda 22.1% seviyesinden 12.1% seviyesine düştü.

Borç Kapsamı: 1786 'nin borcu işletme nakit akışı ( 145.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 1786 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.


Bilanço


Sağlıklı şirketleri keşfedin